Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases

Key facts

  • Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases
  • Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.
  • Source: PR Times
  • Date: March 26, 2026

Direct answer

Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.

Citation
Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases (March 26, 2026), PR Times
Source
PR Times
Date
March 26, 2026
Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.
researchNQ 56/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: March 26, 2026 at 22:54
  • 🔍 Collected: March 28, 2026 at 21:59 (47h 4m after Published)
  • 🤖 AI Analyzed: April 15, 2026 at 03:21 (413h 21m after Collected)
Toray Industries has developed a technology to control the pore size of PMMA (polymethyl methacrylate) porous fibers within a wide range from a few nanometers to approximately 1,000nm. This technology enables the selective adsorption of pathogenic substances responsible for intractable diseases such as autoimmune, cardiovascular, metabolic, neurodegenerative, and cancer. By combining advanced analytical methods like small-angle X-ray scattering with digital technologies for phase-separation simulation, Toray realized a pore-size control technique that achieves pore sizes over 50 times larger than conventional ones while maintaining structural strength. Toray aims for early practical application in treatments and is also exploring uses in biopharmaceutical manufacturing.

FAQ

What is the key advantage of this technology?

It allows for real-time control of PMMA porous fiber pore sizes up to approximately 1,000nm, which is 50 times larger than conventional capabilities, while maintaining structural strength.

What are the key facts in this article?

Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.

What is the direct answer?

Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.

Back to Newsroom (169)